UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 7, 2023

Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-41063 (Commission File Number) 47-1879539 (IRS Employer Identification No.)

9237 E Via de Ventura Blvd, Suite 105 Scottsdale, AZ 85258 (Address of Principal Executive Offices)

or rime par Encount of Sinces,

(480) 434-6670

(Registrant's telephone number, including area code)

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
|---|
| ☐ Written communications pursuant to Rule 425 under the Securities Act. |
| ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |

Securities registered pursuant to Section 12(b) of the Act:

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---------------------|-------------------|---|
| Common Stock | DERM | Nasdag Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square

Item 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 7, 2023, Dr. Jeffrey Paley submitted his resignation from his position as a member of the Board of Directors (the "Board") of Journey Medical Corporation (the "Company"), effective immediately. Dr. Paley did not resign as a result of any disagreement with the Company on any matter, including relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Journey Medical Corporation (Registrant)

Date: December 8, 2023

By: /s/ Claude Maraoui

Claude Maraoui Chief Executive Officer, President and Director